Working… Menu

Causes and Consequences of Primary Ovarian Insufficiency (Clinical POI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04082169
Recruitment Status : Recruiting
First Posted : September 9, 2019
Last Update Posted : September 9, 2019
Information provided by (Responsible Party):
Haukeland University Hospital

Brief Summary:
100 women with primary ovarian insufficiency will be included for extensive diagnostic workup to improve diagnostic precision by extended autoantibody screening and genetic and toxicological testing.

Condition or disease
Primary Ovarian Insufficiency Premature Menopause

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Causes and Consequences of Primary Ovarian Insufficiency
Actual Study Start Date : January 11, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022

Primary Outcome Measures :
  1. Autoimmune [ Time Frame: one day ]
    Prevalence of primary ovarian insufficiency (POI) with autoimmune etiology based on positive autoantibodies toward steroidogenic cells

  2. Genetic [ Time Frame: one day ]
    Prevalence of POI with genetic etiology defined by detection of genetic defects in a NGS panel

  3. Endocrine disrupting chemicals [ Time Frame: one day ]
    Characterize the cohort of women with POI, including testing for environmental factors

Secondary Outcome Measures :
  1. Phenotype description [ Time Frame: one day ]
    Describe phenotypical characteristics including menstrual characteristics, hormone profile, BMD

Biospecimen Retention:   Samples With DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Ovarian insufficiency
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
100 women with primary ovarian insufficiency defined as absence of menstruation more than 4 months and serum level of follicle stimulation hormone (FSH) in menopausal range at 2 or more occations

Inclusion Criteria:Women 40 years or younger, more than 4 months amenorrhea, more than 2 FSH measurements in menopausal range (drawn at least 2 months apart), ability to provide informed concent -

Exclusion Criteria:History of oophorectomy, chemotherapy or radiation


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04082169

Layout table for location contacts
Contact: Eystein Husebye, prof +4755975000

Layout table for location information
HaukelandUH Recruiting
Bergen, Norway
Contact: Elinor Vogt, MD    +4793899380   
Sub-Investigator: Marianne Oksnes, PHD         
Sponsors and Collaborators
Haukeland University Hospital
Layout table for investigator information
Study Chair: Kahtan Al-Azawy, MD Haukeland University Hospital

Layout table for additonal information
Responsible Party: Haukeland University Hospital Identifier: NCT04082169     History of Changes
Other Study ID Numbers: 2018/1206
First Posted: September 9, 2019    Key Record Dates
Last Update Posted: September 9, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Primary Ovarian Insufficiency
Menopause, Premature
Gonadal Dysgenesis
Turner Syndrome
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Disorders of Sex Development
Urogenital Abnormalities
Congenital Abnormalities
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Sex Chromosome Disorders
Chromosome Disorders
Genetic Diseases, Inborn